Literature DB >> 6440792

Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.

M Bialer, A Rubinstein, I Raz, O Abramsky.   

Abstract

The pharmacokinetics of valpromide, a primary amide of valproic acid, was investigated in 6 healthy, adult male volunteers, each of whom was given 900 mg as a marketed, enteric-coated tablet and a solution. Valpromide was biotransformed to valproic acid after the administration of the tablet and the solution with a bioavailability of 0.79 +/- 0.24 and 0.77 +/- 0.12, respectively, relative to a marketed tablet of valproic acid. The absorption of valpromide was not rate-limited by dissolution. As a solid, nonhygroscopic, neutral prodrug of valproic acid, valpromide may be a good alternative to valproic acid and sodium valproate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440792     DOI: 10.1007/bf00549603

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Pharmacokinetics and bioavailability of sodium valproate.

Authors:  U Klotz; K H Antonin
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

2.  A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs.

Authors:  M Bialer; A Rubinstein
Journal:  J Pharm Pharmacol       Date:  1983-09       Impact factor: 3.765

3.  A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats.

Authors:  F Pisani; A Fazio; G Oteri; R Di Perri
Journal:  J Pharm Pharmacol       Date:  1982-01       Impact factor: 3.765

4.  Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma.

Authors:  M Bialer; M Friedman; A Rubinstein
Journal:  J Pharm Sci       Date:  1984-07       Impact factor: 3.534

5.  The antiepileptic properties of N-dipropylacetamide (depamide): a clinical trial.

Authors:  R Musolino; G Gallitto; L Morgante; F Pisani; R Di Perri
Journal:  Acta Neurol (Napoli)       Date:  1980-04

6.  Depamide in the treatment of epilepsy. A clinical trial.

Authors:  P Favel; J Cartier; J P Gratadou; G Gratadou
Journal:  Epilepsia       Date:  1973-09       Impact factor: 5.864

7.  Drug urinary excretion data--some aspects concerning the interpretation.

Authors:  B K Martin
Journal:  Br J Pharmacol Chemother       Date:  1967-02

8.  Pharmacokinetics of valpromide in dogs after various modes of administration.

Authors:  M Bialer; A Rubinstein
Journal:  Biopharm Drug Dispos       Date:  1984 Apr-Jun       Impact factor: 1.627

9.  Systemic interaction between valproic acid and free fatty acids in rhesus monkeys.

Authors:  I Johno; M Y Huang; R H Levy
Journal:  Epilepsia       Date:  1982-12       Impact factor: 5.864

10.  Increased dipropylacetic acid bioavailability from dipropylacetamide by food.

Authors:  F Pisani; A A D'Agostino; A Fazio; G Oteri; G Primerano; R Di Perri
Journal:  Epilepsia       Date:  1982-04       Impact factor: 5.864

View more
  10 in total

1.  Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.

Authors:  M Bialer; A Haj-Yehia; N Barzaghi; F Pisani; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.

Authors:  K Badir; A Haj-Yehia; T B Vree; E van der Kleijn; M Bialer
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

3.  Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.

Authors:  O Spiegelstein; B Yagen; R H Levy; R H Finnell; G D Bennett; M Roeder; V Schurig; M Bialer
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

Review 4.  Clinical pharmacology of valpromide.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

5.  Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.

Authors:  A Haj-Yehia; M Bialer
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

6.  Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.

Authors:  F Pisani; A Fazio; C Artesi; G Oteri; E Spina; T Tomson; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

7.  Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.

Authors:  F Pisani; A Fazio; G Oteri; E Spina; E Perucca; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

Review 8.  Can we develop improved derivatives of valproic acid?

Authors:  M Bialer; A Haj-Yehia; K Badir; S Hadad
Journal:  Pharm World Sci       Date:  1994-02-18

Review 9.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 10.  Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.

Authors:  Manish Kumar Mishra; Samiksha Kukal; Priyanka Rani Paul; Shivangi Bora; Anju Singh; Shrikant Kukreti; Luciano Saso; Karthikeyan Muthusamy; Yasha Hasija; Ritushree Kukreti
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.